The Value of Screening HIV-Infected Individuals for Didanosine-Related Liver Disease?

Schiano T.D. , Kotler D.P. , Ferran E. , Fiel M.I. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102: 2536–2540.

Mallet V. , Blanchard P. , Verkarre V. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187–192.

Saifee S. , Joelson D. , Braude J. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6: 1167–1169.

Maida I. , Garcia-Gasco P. , Sotgiu G. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13: 103–107.

Kovari H. , Ledergerber B. , Peter U. Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626–635.

Merchante N. , Pérez-Camacho I. , Mira J.A. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010; 15: 753–763.